Recruiting

Long-term safety study of a new rheumatoid arthritis medication

Plain-English translation of NCT06887127 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Read our Rheumatoid Arthritis research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a long-term safety and effectiveness study of , a new medication for rheumatoid arthritis. You would be eligible if you already completed a previous trial testing this medication. Everyone in this study takes the same dose of for 18 weeks to see how well it works and how safe it is over time.

While earlier trials showed promise, doctors need to understand how this medication works and how safe it remains when patients take it for a longer period. This study will help them make sure the treatment is truly helping people with rheumatoid arthritis without causing unexpected problems.

Do you qualify?

You likely qualify if…

you completed the earlier TLL-018-301 study within the last 3 months
you are between 18 and 75 years old
you are willing to use effective contraception for at least 90 days during and after the study (if you can become pregnant)
you understand the study and are willing to sign a consent form
you do not have a severe allergic reaction to this medication from the earlier study

You likely don't qualify if…

you had a severe allergic reaction to the medication in the earlier study
you have had shingles, a major heart event, blood clots, or certain blood disorders since the earlier study
you have a serious heart, lung, or other unstable medical condition that could be unsafe
you have abnormal lab test results at screening
you have active tuberculosis or untreated latent tuberculosis infection

What participation looks like

You would take two 10 mg tablets of by mouth twice daily for 78 weeks (about 18 months). You'll visit the clinic at weeks 6, 12, 24, 36, 48, 60, 72, and 78 for safety checks including blood tests, physical exams, and vital signs. The study will also assess how well your rheumatoid arthritis is controlled using joint exams, questionnaires, and blood tests at regular intervals.

AI-generated summary from trial data · Jun 11, 2026 · Not medical advice

Trial locations(1 site)

China

Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality